A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Owen, Dwight Hall
Bunn, Paul A.
Johnson, Bruce E.
Kwiatkowski, David J.
Kris, Mark G.
Wistuba, Ignacio Ivan
Gandhi, Mayank
Phan, See
Shames, David S.
Schulze, Katja
Yu, Wei
Aisner, Dara
Chaft, Jamie E.
Garon, Edward B.
Lee, Jay M.
Minna, John D.
Rusch, Valerie W.
Reckamp, Karen L.
Wozniak, Antoinette J.
Carbone, David P.
机构：
[1] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[2] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Genentech Inc, San Francisco, CA USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[8] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[9] City Hope Comprehens Canc Ctr, Duarte, CA USA
[10] Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS8580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8580
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non Small Cell Lung Cancer (NSCLC)
    Owen, Dwight
    Bunn, Paul, Jr.
    Johnson, Bruce
    Kwiatkowski, David
    Kris, Mark
    Wistuba, Ignacio
    Gandhi, Mayank
    Phan, See
    Shames, David
    Schulze, Katja
    Bernaards, Coen
    Aisner, Dara
    Chaft, Jamie
    Gainor, Justin
    Lee, Jay
    Minna, John
    Mino-Kenudson, Mari
    Garcia-Prieto, Celia
    Rusch, Valerie
    Sabichi, Anita
    Villaruz, Liza
    Wozniak, Antoinette
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1082 - S1082
  • [2] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
  • [3] Neoadjuvant atezolizumab plus chemotherapy in resectable non-small cell lung cancer (NSCLC).
    Shu, Catherine A.
    Grigg, Claud
    Chiuzan, Codruta
    Garofano, Robert F.
    Patel, Vijeta
    Hernandez, Susana
    Negri, Tiffany
    Sacher, Adrian G.
    Smith-Marrone, Stephanie
    Stoopler, Mark
    Gainor, Justin F.
    Awad, Mark M.
    D'Ovidio, Frank
    Sonett, Joshua R.
    Bacchetta, Matthew
    Saqi, Anjali
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Neoadjuvant therapy for resectable non-small cell lung cancer
    Welcker, Katrin
    Jonigk, Danny
    Kropf-Sanchen, Cornelia
    Tufman, Amanda
    Draube, Andreas
    Stenzinger, Albrecht
    Zaatar, Mohamed
    Thomas, Michael
    PNEUMOLOGIE, 2025, 79 (01): : 16 - 24
  • [5] A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)
    Wang, Ting
    Huang, Lu Li Lin
    Liu, Jie Wei
    Zhu, Da Xing
    Dong, Jing Si
    Deng, Han Yu
    Zheng, Xi
    Tian, Long
    Jiang, Li Li
    Wang, Wei Ya
    Zhou, Ping
    Su, Ming Gang
    Pu, Dan
    Cai, Xu Yu
    Feng, Ming Yang
    Ou, Xue Jin
    Wang, Yongsheng
    Zhou, Qing Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC)
    Depierre, A
    Milleron, B
    Moro, D
    Quoix, E
    Lebeau, B
    Chastang, C
    Braun, D
    Janicot, H
    Paillot, N
    Gouva, S
    Coudert, B
    Breton, JL
    Lemarie, E
    Lebas, FX
    Coetmeur, D
    Thiberville, L
    Brehot, JM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1053 - 1053
  • [7] AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
    Ross, Helen J.
    Kozono, David E.
    Urbanic, James John
    Williams, Terence Marques
    DuFrane, Carter
    Bara, Ilze
    Schulze, Katja
    Brockman, Jane Michelle
    Wang, Xiaofei F.
    Gao, Junheng
    Vokes, Everett E.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Phase II pilot study of induction erlotinib therapy in patients with resectable non-small cell lung cancer to select postoperative adjuvant therapy
    Lee, Dae Ho
    Hong, Yong Sang
    Kim, Tae Won
    Jung, Kyung Hae
    Kim, Sang -We
    Suh, Cheolwon
    Lee, Jung -Shin
    Kim, Heung Tae
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] Adjuvant or neoadjuvant therapeutic strategy for resectable non-small cell lung cancer
    Hayashi, Ryuji
    RESPIRATORY INVESTIGATION, 2023, 61 (02) : 133 - 134
  • [10] Phase II study of Neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer
    Ramnath, N
    Sommers, E
    Robinson, L
    Nwogu, C
    Sharma, A
    Cantor, A
    Bepler, G
    CHEST, 2005, 128 (05) : 3467 - 3474
12345